Medline ® Abstract for Reference 71
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia.
Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J
Eur J Cancer. 1997;33(2):297.
Docetaxel is a new taxoid antineoplastic agent with clinical efficacy especially in breast cancer. One of the most distressing side-effects induced by docetaxel is alopecia. We studied the prevention of alopecia by using a cold cap in 98 patients receiving 100 mg/m2 docetaxel by 1 h i.v. infusion every 3 weeks. One patient was lost to follow-up. 83 patients (86%) were evaluated as a success to the cold cap, as they presented WHO grade alopecia<or = 2 and no need to wear a wig. 14 patients (14%) had to wear a wig; among them; 7 patients withdrew before the evaluation at three cycles. The cold cap is a very effective technique with minimal side-effects for docetaxel-treated patients.
Centre Oscar Lambret, Lille, France.